Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Introduction to Nuclear Reprogramming

Introduction to Nuclear Reprogramming

Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multiple incomplete surgical and procedural interventions correlate with hyperprogression of a pleomorphic dermal sarcoma - a case report.

Journal of surgical case reports·2026

Same author

Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.

Oncotarget·2026

Same author

Protocol for incomplete murine tumor resection to study local effects of surgical trauma on residual sarcoma.

STAR protocols·2026

Same author

What factors differentiate early from late pulmonary metastases in soft-tissue sarcoma of the limbs? : a comparative cohort analysis.

The bone & joint journal·2026

Same author

Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.

Cancer discovery·2026

Same author

Detection of Extracellular Vesicles with Colocalized Surface Markers via a Capture-Release-Capture Strategy for Treatment Monitoring in Ewing Sarcoma.

Advanced healthcare materials·2026

Same journal

Adenosine as a metabolic checkpoint in CD8+ T cell dysfunction.

Trends in immunology·2026

Same journal

IL-33 scripts cancer immunity.

Trends in immunology·2026

Same journal

Mitochondrial Ca<sup>2+</sup> signaling: A metabolic rheostat defining tumor and immune cell fate.

Trends in immunology·2026

Same journal

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026

Same journal

Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease.

Trends in immunology·2026

Same journal

Metabolic regulatory nodes of the inflammasome and inflammatory cell death.

Trends in immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 1, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Reprogramming antitumor immunity.

Joseph G Crompton¹, David Clever², Raul Vizcardo³

¹National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 2QH, UK; Department of Surgery, University of California Los Angeles, Los Angeles, CA 90095, USA.

Trends in Immunology

|March 26, 2014

Summary

This summary is machine-generated.

Regenerative medicine techniques can be repurposed to treat metastatic cancer. By revitalizing the immune system, cellular reprogramming offers a novel approach to cancer therapy.

Keywords:

T cell reprogramming cancer immunotherapy regenerative medicine

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: May 1, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

Regenerative Medicine
Cancer Biology
Immunology

Background:

Regenerative medicine effectively replaces tissues and organs damaged by disease or injury.
Cellular reprogramming principles are established in regenerative medicine but less so for cancer treatment.

Purpose of the Study:

To review cellular reprogramming techniques in regenerative medicine.
To explore the expansion of regenerative medicine for treating metastatic cancer.
To propose immune system revitalization as a therapeutic strategy.

Main Methods:

Overview of existing cellular reprogramming methodologies.
Contextual analysis of regenerative medicine applications.
Conceptual framework for applying reprogramming to cancer immunotherapy.

Main Results:

Cellular reprogramming is a key tool in regenerative medicine.
Metastatic cancer treatment remains an underexplored area for cellular reprogramming.
Revitalizing exhausted and senescent immune cells is a potential therapeutic avenue.

Conclusions:

Cellular reprogramming offers a promising, yet underexplored, avenue for cancer therapy.
Expanding regenerative medicine principles to cancer treatment requires further investigation.
Immune system revitalization through reprogramming could combat metastatic disease.